SSI Investment Management Inc. decreased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 1.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,568 shares of the medical research company’s stock after selling 34 shares during the quarter. SSI Investment Management Inc.’s holdings in Amgen were worth $442,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in AMGN. BlackRock Inc. raised its stake in shares of Amgen by 1.9% in the 2nd quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after buying an additional 909,689 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Amgen by 45.9% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,158,831 shares of the medical research company’s stock valued at $373,096,000 after buying an additional 679,144 shares in the last quarter. Canada Pension Plan Investment Board raised its stake in shares of Amgen by 65.7% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,706,261 shares of the medical research company’s stock valued at $293,869,000 after buying an additional 676,300 shares in the last quarter. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Amgen in the 1st quarter valued at $110,402,000. Finally, Bank of Nova Scotia increased its position in shares of Amgen by 414.4% during the 1st quarter. Bank of Nova Scotia now owns 601,862 shares of the medical research company’s stock worth $98,747,000 after purchasing an additional 484,868 shares in the last quarter. Institutional investors own 78.38% of the company’s stock.

In related news, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $171.58, for a total transaction of $261,659.50. Following the transaction, the executive vice president now directly owns 57,631 shares in the company, valued at approximately $9,888,326.98. The disclosure for this sale can be found here. Insiders sold a total of 7,050 shares of company stock worth $1,239,673 in the last ninety days. Insiders own 0.19% of the company’s stock.

A number of equities research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Amgen from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Royal Bank Of Canada dropped their target price on shares of Amgen from $192.00 to $188.00 and set a “sector perform” rating for the company in a research report on Thursday, October 26th. Credit Suisse Group reiterated a “neutral” rating and set a $186.00 target price (up previously from $177.00) on shares of Amgen in a research report on Friday, September 29th. Oppenheimer reiterated a “buy” rating and set a $203.00 target price on shares of Amgen in a research report on Thursday, September 7th. Finally, BMO Capital Markets reiterated a “hold” rating and set a $199.00 target price on shares of Amgen in a research report on Monday, September 25th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $190.22.

Amgen, Inc. (AMGN) opened at $176.22 on Thursday. The stock has a market cap of $129,712.96, a PE ratio of 14.20, a PEG ratio of 2.59 and a beta of 1.36. The company has a debt-to-equity ratio of 1.05, a current ratio of 6.07 and a quick ratio of 5.72. Amgen, Inc. has a one year low of $138.83 and a one year high of $191.10.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.11 by $0.16. The company had revenue of $5.77 billion for the quarter, compared to analyst estimates of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The company’s revenue for the quarter was down .7% on a year-over-year basis. During the same quarter last year, the firm earned $3.02 EPS. sell-side analysts expect that Amgen, Inc. will post 12.66 earnings per share for the current fiscal year.

Amgen declared that its board has authorized a stock repurchase program on Wednesday, October 25th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire shares of its stock through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Friday, November 17th will be paid a $1.15 dividend. This represents a $4.60 annualized dividend and a dividend yield of 2.61%. The ex-dividend date is Thursday, November 16th. Amgen’s dividend payout ratio (DPR) is presently 41.63%.

TRADEMARK VIOLATION NOTICE: “SSI Investment Management Inc. Sells 34 Shares of Amgen, Inc. (AMGN)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/12/07/ssi-investment-management-inc-sells-34-shares-of-amgen-inc-amgn.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.